health pharma news today obesity drugs glp-1 today How Supply and Demand for Weight Loss is Playing Out in 2026 GLP-1 Drug Market: the rapid
Description
Many patients remain on treatment for a year or longer
In a matched pair casecontrol study done by Kobori et al
It should not be driven by myths, fears, or social media exaggerations that misrepresent clinical reality
Medicare Part D Claims for GLP-1s (CY 2018 to 2022) The expanded indication for Wegovy is expected to increase spending on this medication class
Compared to the GLP-1 cohort, the tirzepatide group was younger (mean age 55.1 years vs
Preclinical studies consistently show neuroprotective effects of GLP-1RAs in PD models
